Clinical trials: sponsored by British Columbia Cancer Agency
Neoplasm Metastasis, Neoplastic Processes
SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases
The primary objective is to patient-reported Quality of Life related to complete control of Radiation Induced Nausea and Vomiting (RINV) between standard palliative radiotherapy and VMAT.
- Conditions
- Neoplasm Metastasis, Neoplastic Processes, Neoplasms, Pathologic Processes
- Trial name
- NCT03694015
- Testing
- SUPR, VMAT
- Where
- 5 sites in Canada
- Volunteers
- 160 people
- Sponsor
- British Columbia Cancer Agency
Hodgkin Lymphoma
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
The aim of this study is to improve the chance of cure for people with higher risk Hodgkin lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study drug called Nivolumab when combined with ABVD…
- Trial name
- NCT03033914
- Testing
- doxorubicin, Bleomycin, vinblastine
- Where
- 10 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Vulvar Cancer
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials.
- Trial name
- STRIVE (NCT05576831)
- Testing
- Re-excision
- Where
- Canada
- Volunteers
- 249 people
- Sponsor
- British Columbia Cancer Agency
Early Stage Breast Cancer
Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant
Permanent Breast Seed Implant (PBSI) has been demonstrated to be a well accepted and well tolerated form of partial breast radiotherapy.
- Trial name
- PBSI (NCT02297672)
- Testing
- Stranded palladium seed interstitial implant, 3 dimensional breast ultrasound, Computerized tomography (CT)
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- British Columbia Cancer Agency
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy.
- Trial name
- BrachyQOL (NCT01936883)
- Testing
- HDR, LDR
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
LDR vs. HDR Brachytherapy for Prostate Cancer
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy.
- Trial name
- LDR/HDRmono (NCT03426748)
- Testing
- Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- British Columbia Cancer Agency
Hereditary Cancer Syndrome
Cell-free DNA in Hereditary And High-Risk Malignancies 1
The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS).
- Trial name
- CHARM1 (NCT04261972)
- Testing
- Next generation sequencing (NGS)
- Where
- 7 sites in Canada
- Volunteers
- 1,416 people
- Sponsor
- University Health Network, Toronto
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
- Trial name
- NCT05570994
- Testing
- 177Lu HTK03170, 68Ga-HTK03149
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors.
- Trial name
- NCT06129084
- Testing
- FGFR Testing
- Where
- 7 sites in Canada
- Volunteers
- 260 people
- Sponsor
- Bernie Eigl
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Prostate Adenocarcinoma
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have…
- Trial name
- NCT07251829
- Testing
- Prostatic Artery Embolization
- Volunteers
- 35 people
- Sponsor
- Srinivas Raman
Metastatic Cancers, Advanced Cancers
Personalized Oncogenomics (POG) Program of British Columbia
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy.
- Conditions
- Metastatic Cancers, Advanced Cancers, Cancers That Cannot be Treated With Curative Intent
- Trial name
- NCT02155621
- Testing
- Genome sequencing
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- British Columbia Cancer Agency
Pain, Nausea
Cannabis For Cancer-Related Symptoms
Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms.
- Conditions
- Pain, Nausea, Anxiety, Sleep Disturbance
- Trial name
- CAFCARS (NCT03948074)
- Testing
- Cannabis
- Where
- 8 sites in Canada
- Volunteers
- 91 people
- Sponsor
- Pippa Hawley
Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options.
- Trial name
- NCT06665178
- Testing
- Sacituzumab Govitecan
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasm, Prostatic Cancer
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer…
- Trial name
- NCT04484701
- Testing
- 68Ga-PSMA-11
- Where
- Canada
- Volunteers
- 1,574 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Metastases
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
- Trial name
- SABR PRIMER (NCT06937281)
- Testing
- SABR
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Meningioma
DOTATATE PET for Meningioma Radiation Planning
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in…
- Trial name
- DOTATATE-RT (NCT06937268)
- Testing
- DOTATATE-PET scan
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Human Papillomavirus Infection
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is…
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus, Cervical Dysplasia
- Trial name
- NCT06915779
- Where
- 13 sites in Canada
- Volunteers
- 241 people
- Sponsor
- University of British Columbia